TX-PLANVIEW
10.5.2021 15:02:12 CEST | Business Wire | Press release
Planview, a global leader in Portfolio Management and Work Management, today announced the appointment of Razat Gaurav as Chief Executive Officer, effective immediately. Gaurav, who is also joining the Company’s Board of Directors, succeeds Greg Gilmore, who is retiring and will continue to serve on the Board of Directors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210510005500/en/
With more than 20 years of experience in the enterprise software space, Gaurav brings proven leadership in scaling and growing businesses on a global basis. Most recently, Gaurav served as CEO of LLamasoft, where he was instrumental in driving an expanded product vision for AI based supply chain design and decision making. This vision, combined with a purpose-driven culture, enabled the company to more than double its revenue in three years and resulted in a successful $1.5 billion acquisition by Coupa in November 2020. Earlier in his career, Gaurav held leadership positions at Blue Yonder, i2 Technologies, and Ernst & Young’s management consulting practice. He also served on the Board of Directors of Sparta Systems (since acquired by Honeywell) and LLamasoft.
“Enterprises today are grappling with massive change and a surge in digital transformation initiatives – and the way teams work to turn strategy into outcomes has to evolve,” said Gaurav. “Planview has a rich history of technology innovation and industry leadership, as well as a proven track record of partnering with customers to transform their enterprises to meet the demands of our changing environment. I’m pleased to join Planview at an exciting time in the company’s growth trajectory and look forward to working with the team to reimagine the future of digital transformation in the enterprise.”
Gaurav’s appointment marks the next step for Planview as it looks to further accelerate its growth. Most recently, Planview acquired Clarizen and Changepoint , advancing the Company’s leadership in Portfolio Management and Work Management, and creating an unmatched community of Agile leaders, PMOs, PPM, and Professional Services Automation (PSA) practitioners. In December 2020, the company was acquired by private equity firms TPG and TA Associates for $1.6 billion .
“I have had the privilege of knowing Razat for several years and have seen firsthand his ability to build technology businesses that create differentiated value for their customers. His track record of driving growth through innovation and company culture makes him a perfect fit for Planview,” said Nehal Raj, Partner at TPG Capital. “ On behalf of the Board, I want to thank Greg for his leadership and stewardship of Planview for more than 25 years. We wish him the best in his retirement and appreciate his continued service on the board.”
“Under Greg's leadership, Planview has established itself as an industry leader and trusted partner to its customers,” said Ashu Agrawal, a Managing Director at TA Associates. “Looking ahead, we are confident that Razat brings the ideal combination of digital transformation expertise and experience successfully scaling enterprise software businesses to lead Planview through its next chapter. We’re pleased to welcome him aboard.”
“It has been an honor and a privilege to help lead Planview for the last 25 years, and to work alongside such extraordinary colleagues, customers, and partners,” said Gilmore. “I’m proud of the accomplishments and results we have delivered as a company, and believe that Planview is well positioned for exceptional success in the years to come.”
About Planview
Planview has one focus: enabling the transformation journey as organizations rewire strategy to delivery in today’s fast-paced, highly disruptive markets. Our solutions enable organizations to navigate this journey and accelerate on-strategy delivery at enterprise scale. Planview’s full spectrum of Portfolio Management and Work Management solutions create organizational focus on the strategic outcomes that matter and empower teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enable customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, Planview has more than 1,000 employees supporting 4,500 customers and 1.3 million users worldwide. For more information, visit: www.planview.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210510005500/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
